John Hohneker, MD
Home
About Us
Structure
Current Events
Past Events
Video Gallery
Policy & Reports
Awards
Media Coverage
Internship/Volunteers
Legal
Contact Us
 
 
John Hohneker, MD
President & CEO
Anokion US

Prior to joining Anokion as CEO, John was President of Research and Development at FORMA Therapeutics Inc., where he guided the company’s transition from a discovery-stage biotech to one with programs in clinical trials. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, most recently as senior vice president and global head of development for immunology and dermatology. During his tenure at Novartis, John played a key role in the development, approval, and commercialization of products including Cosentyx®, Xolair®, Ilaris®, Gleevec®, Tasigna®, Zometa®, Afinitor® and Exjade®. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. He currently serves on the board of directors of Torque Therapeutics, Inc., a privately held biotechnology company. He also previously served on the board of directors of Dimension Therapeutics Inc., which was acquired by Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

John received a bachelor’s degree in chemistry from Gettysburg College and an M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School. He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina Hospitals.

© 2007 - USA India Chamber of Commerce Home | About us | Policy | Events | Photo Gallery | Awards | Media Coverage | Legal | Contact us